Perovskite solar cells from the slot die coater - a step towards industrial production
The wet coating with a standard ink composition: the wet perovskite thin films (left) has a rib-like structure. The corresponding SEM image (right) of the annealed perovskite film shows inhomogeneities. © HZB
The wet coating with the optimised ink composition (left) is nearly perfectly even. The corresponding SEM image (right) of the annealed perovskite film shows much less inhomogeneities. © HZB
Solar cells made from metal halide perovskites achieve high efficiencies and their production from liquid inks requires only a small amount of energy. A team led by Prof. Dr. Eva Unger at Helmholtz-Zentrum Berlin is investigating the production process. At the X-ray source BESSY II, the group has analyzed the optimal composition of precursor inks for the production of high-quality FAPbI3 perovskite thin films by slot-die coating. The solar cells produced with these inks were tested under real life conditions in the field for a year and scaled up to mini-module size.
Metal halide perovskites are considered to be a particularly low-cost and promising class of materials for next-generation solar modules. Perovskite solar cells can be produced with coating processes using liquid inks made from precursor materials and various solvents. After coating, the solvents evaporate and the perovskites crystallise to form a more or less homogeneous layer.
Options for upscaling
Prof. Dr. Eva Unger's team at Helmholtz-Zentrum Berlin has extensive expertise in solution-based processing methods and is investigating options for upscaling. "Perovskite photovoltaics is the best solution-processable PV technology available," says Eva Unger, "but we are only just beginning to understand how the complex interaction of the solvent components affects the quality of the perovskite layers."
Variations of viscosity
This is because when the halide perovskite layers are coated on large surfaces, unwanted inhomogeneities can occur, for example so-called ribbing structures. "By varying the viscosity of the ink, such effects can be minimised," says Jinzhao Li, who is doing his PhD with Unger. At BESSY II, he has investigated how different solvent combinations affect the crystallisation of the perovskite films. The best p-i-n-FAPbI3 perovskite solar cells thus achieve a certified efficiency of 22.3 % on a laboratory scale. Jinzhao Li also produced mini solar modules (active area of 12.6 cm2) with colleagues from the HySPRINT innovation lab and PVcomB, which achieved efficiencies of around 17 %.
Outdoor test for one year
Dr Carolin Ulbrich's team tested the optimised solar cells at PVcomB’s outdoor test facility for a whole year: In the process, the efficiency remained almost stable in winter and spring, and only dropped in the warmer summer months. "These tests of larger modules under real conditions give us valuable information on degradation mechanisms to then further improve the long-term stability of halide perovskite photovoltaics," says Eva Unger.
- Protein crystallography at BESSY II: faster, better and more and more automaticMany diseases are linked to malfunctions of proteins in the organism. The three-dimensional architecture of these molecules is often highly complex, but it can provide valuable insights into biological processes and the development of drugs. X-ray diffraction at the MX beamlines of BESSY II can be used to decipher the 3D structure of proteins. To date, more than 5000 structures have been solved at the three MX beamlines. Here, we present a review and an outlook with Manfred Weiss, head of the research group for macromolecular crystallography.
- Humboldt-Fellow at HZB-Institute for Solar Fuels: Alexander R. UhlAlexander R. Uhl, UBC Okanagan School of Engineering in Kelowna, Canada, aims to develop with Roel van de Krol from the HZB Institute for Solar Fuels an efficient and inexpensive photoelectrolyser for producing hydrogen using sunlight. His stay is being funded by the Alexander von Humboldt Foundation.
- 5000th protein structure at BESSY II: Starting point for a COVID drugMany proteins have a complex architecture that enables biological functions. Molecules can bind to specific sites on a protein and alter its function. A team at HZB has now investigated the Nsp1 protein, which plays a role in infection with the SARS-CoV-2 virus. They analysed protein crystals, previously mixed with molecules from a fragment library, and discovered a total of 21 candidates as starting points for drug development. At the same time, they also decoded the 5000th structure at BESSY II.